发布于: | 雪球 | 转发:0 | 回复:2 | 喜欢:0 |
$康乃德生物(CNTB)$ Atopic Dermatitis (AD): • Achieved primary and key secondary outcomes at Week 16 in both global Phase 2b and China pivotal/stage 1 trials with > 475 patients with moderate-to-severe AD • Efficacy observed with both 300mg Q2W and 300mg Q4W doses in the...
先声和康乃德的表述不一致,先声说需要和CDE沟通后才知道,康乃德说2023年初沟通,不需要做三期。康诺亚以前沟通不需要52周临床数据,后来所以补充数据,比预期晚了。在3月底或者4月初,得到CDE沟通结果